The Food and Drugs Authority (FDA), has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima, for clinical trials in January 2021.
The Food and Drugs Authority (FDA), has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima, for clinical trials in January 2021.